Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Theralink Technologies Moves Closer Toward Changing the Standard of Care for All Women Newly Diagnosed with HER2+ Breast Cancer

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

February 22, 2021

Theralink Technologies was recently named commercial provider of its patented Reverse Phase Protein Array (RPPA) technology for breast cancer patients if the proposed study has a positive outcome.

George Mason and Rutgers’ collaboration recently received the U.S. Army’s prestigious Breast Cancer Research Program (BCRP) Breakthrough Award. From here, the project’s overall goal is clinical validation – equating to a new way for measuring HER2+ breast cancer based on the tumor’s activation (phosphorylation) state. Further, the measurement in the form of the Theralink® assay, may be predictive, by using only the patient’s diagnostic biopsy, to determine whether or not that patient will respond favorably to the treatment.

“This is a massive step forward, further validating what has been previously proven through the nationally recognized ISPY2 trials– that Theralink’s patented RPPA technology might mean a change in the Standard of Care for all women newly diagnosed with HER2+ breast cancer,” said Mick Ruxin, M.D., President & CEO of Theralink Technologies. “This cohort of patients accounts for approximately 25 percent of all US women’s breast cancer or upwards of 70,000 patients annually. It may be a game changer in the world of oncology and may make a meaningful impact on so many cancer patients.”

Theralink’s RPPA testing measures the direct activation state for dozens of drug targets at once. This can potentially provide oncologists with key information about the patient’s specific tumor and possible clinical pathways.

“We’ve partnered with Theralink who will be responsible for the assay commercialization and expanded clinical assessment to provide possible accelerated adoption and clinical use by medical oncologists,” said Emanuel Petricoin, CAPMM co-director, and a scientific advisor to the Company. “We have set up the infrastructure to quickly deploy the information and technology; if this holds true, we have a commercial partner ready to take it to the bedside as part of a patient clinical care plan and treatment decision support tool.”

“The rigorous blinded validation of the new test with our Rutgers colleagues will be the first step toward potentially realizing an important clinical impact for breast cancer,” said Lance A. Liotta M.D. PhD, Co-Director Center for Applied Proteomics and Molecular Medicine, Medical Director Clinical Proteomics Lab College of Science, George Mason University.

For more clinical information on the George Mason University and Rutgers Cancer Institute of New Jersey collaboration, visit here.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine